DCTH
Delcath Systems, Inc.
DCTH has the edge over UNH overall, supported by stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
DCTH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
DCTH's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
DCTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 117x | $18.66 | -13% |
| Current | 134x | $21.38 | — |
| Fair | 166x | $26.50 | +24% |
| Forward | 1,071x | $21.38 | — |
| Expensive | 1,435x | $230 | +974% |
Historical ranges are pointers, not guarantees.
DCTH has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
DCTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect DCTH to return to profit, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
DCTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | -88% |
| Q3 2026 | $0.16 | +167% |
| Q2 2026 | $0.01 | -90% |
| Q1 2026 | $0.01 | +$0.46 |
| Q4 2025 | $0.07 | +$1.00 |
| Q3 2025 | $0.06 | +$1.38 |
| Q2 2025 | $0.10 | +$2.62 |
| Q1 2025 | -$0.45 | +$2.17 |
| Q4 2024 | -$0.93 | +$2.01 |
DCTH has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
DCTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +71% |
| Q2 2026 | $29.1M | +21% |
| Q1 2026 | $25M | +26% |
| Q4 2025 | $20.7M | +37% |
| Q3 2025 | $20.6M | +84% |
| Q2 2025 | $24.2M | +211% |
| Q1 2025 | $19.8M | +530% |
| Q4 2024 | $15.1M | +2701% |
DCTH has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +22 points |
| Q2 2026 | 8.2% | -2.5 points |
| Q1 2026 | -6.5% | -9.8 points |
| Q4 2025 | -11% | -31 points |
| Q3 2025 | -1.9% | +9.3 points |
| Q2 2025 | 11% | +61 points |
| Q1 2025 | 3.3% | +331 points |
| Q4 2024 | 20% | +2117 points |
DCTH has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
DCTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +60% |
| Q2 2026 | $5.2M | -24% |
| Q1 2026 | $287K | -86% |
| Q4 2025 | $7.7M | +$8.9M |
| Q3 2025 | $4.3M | +$8.2M |
| Q2 2025 | $6.9M | +$11.4M |
| Q1 2025 | $2.1M | +$11.7M |
| Q4 2024 | -$1.2M | +$7M |
DCTH has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
DCTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.3M shares |
| 1 year | +2.4% | +963K shares |
| 3 years | +229% | +28.6M shares |
| 5 years | +514% | +34.3M shares |
DCTH has 41M diluted shares, up 2.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $11,000 |
| Q1 2026 | $3M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over DCTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
DCTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.0x | Net Cash |
| Q4 2025 | -44.2x | Net Cash |
| Q3 2025 | -6.8x | Net Cash |
| Q2 2025 | -6.5x | Net Cash |
DCTH has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
DCTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.6 | Overbought |
| Stochastic | 60.2 | Neutral |
DCTH's weekly RSI is 77 (overbought) and its Stochastic is 60 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
DCTH PE vs Healthcare Sector
| Metric | DCTH | Sector median | Relative |
|---|---|---|---|
| PE | 134x | 26x | 417% above |
| PE % | 26 | 29 | 3 pts below |
DCTH is trading at 134x earnings, a 417% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over DCTH on valuation relative to its sector.
DCTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 37% above |
| 20 week MA | $15.1 | 41% above |
| 50 week MA | $12.2 | 75% above |
| 100 week MA | $12.3 | 73% above |
| 200 week MA | $9.19 | 133% above |
DCTH has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
DCTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.0 | $17.1 | -29% |
| 2021 | $17.1 | $8.45 | -51% |
| 2022 | $8.45 | $3.59 | -58% |
| 2023 | $3.59 | $4.16 | +16% |
| 2024 | $4.16 | $12.0 | +188% |
| 2025 | $12.0 | $10.3 | -14% |
| 2026 YTD | $10.3 | $21.4 | +108% |
DCTH has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.